TO THE EDITOR-Our institution began using the Sofia fluorescent immunoassay analyzer (Quidel Corp ., San Diego, CA) [1] as our point-of-care test (POCT) for influenza beginning in 2013.We calculated the percent positivity for influenza B as follows:
number of POCTs positive for influenza B total number of POCTs positive for influenza A or B Â 100
The monthly mean percent positivites for B were 27%, 26%, 29%, and 49% for September, October, November, and December 2013, respectively. We observed 55% positivity for B in January 2014 and 58% for the first 2 weeks of February. Because these percentages were much greater than the national average of <4% [2] , we compared the results obtained with the POCT to those obtained with the eSensor respiratory viral panel (RVP; GenMarkDx, Carlsbad, CA). This test distinguishes influenza A subtypes, including the 2009 pandemic H1N1 ( pH1N1), from nonpandemic H1N1 and H3N2, as well as influenza B and several other common respiratory viruses. When the POCT yielded a positive result for influenza A or B, a second specimen was immediately obtained and analyzed using the RVP. We compared 43 POCT A/RVP paired specimens and 66 POCT B/RVP paired specimens (Figure 1 ). For influenza A, 93% of those samples were identified as pH1N1 by our RVP. Seven percent were negative for any respiratory virus, which is consistent with the expected performance of the RVP [3] . In contrast, for influenza B, only 1 specimen was positive for influenza B by RVP and no respiratory virus was detected in 47% of the specimens. Thirty-eight percent of the specimens were positive for a noninfluenza virus, and pH1N1was detected in 14% of the specimens.
Quality control testing did not reveal any issues with the performance of the POCT lot numbers that were used. The staff performing the POCT was retrained by representatives from the manufacturer as well as our internal point-of-care staff. Despite 3 training sessions that involved approximately 50% of the staff performing the POCT, we observed no decrease in the influenza B percent positivity. Because of concern that approximately 85% of patients with a positive POCT for influenza B were misdiagnosed and may have been inappropriately treated with neuraminidase inhibitors, we stopped using this test in mid-February and now rely on the RVP to confirm a clinical diagnosis of influenza in admitted patients. We propose that caution is advised when relying on a rapid POCT to diagnose influenza, particularly when a result of influenza B is obtained with this product. were negative for influenza (38% nonflu virus plus 47% negative).
